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Abstract
Using data from a nationally representative survey, we identified predictors of chlamydial 
infection in women aged 26 to 39 years. Chlamydia prevalence was low overall but varied by 
sociodemographics and sexual behaviors. Findings support current recommendations that women 
older than 25 years should not be routinely screened for chlamydial infection.
Because most chlamydial infections and complications in women are asymptomatic, 
screening is necessary to detect and treat infections. However, routine screening is likely 
only cost-effective in populations with a prevalence above a minimum threshold (e.g., 3%),1 
and screening criteria are needed to identify populations most at risk. Chlamydia burden is 
highest in young women,2,3 and the Centers for Disease Control and Prevention (CDC) 
recommends that all sexually active women 25 years or younger receive annual chlamydia 
screening.4 For women older than 25 years, the CDC recommends screening those with 
“risk factors” for chlamydia4; however, these risk factors have not been fully elucidated.
Data collected on sexually active women enrolled in commercial and Medicaid health plans 
suggest that chlamydia screening coverage for women 25 years or younger remains low, 
with less than 60% of sexually active women screened annually.5 Overscreening female 
older than 25 years, a population with lower chlamydia prevalence, is common. For 
example, in Title X family planning clinics, 42% of female clients 25 years or older were 
screened for chlamydia, accounting for nearly 40% of all chlamydia tests conducted in Title 
X clinics in 2010.6 Overscreening older women strains the already limited resources needed 
to ensure adequate chlamydia screening coverage for younger women.7 Hence, there is a 
need for better (evidence-based) chlamydia screening criteria for older women.
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Screening criteria are often created by retrospectively looking at characteristics of women 
tested in clinics to identify predictors of chlamydial infection.8 One of the limitations of 
using clinic-based chlamydia positivity data to identify screening recommendations is the 
representativeness of the patient population. Women seeking care in clinics may have a 
higher chlamydia prevalence than the general population (i.e., women may seek care for 
reasons related to chlamydial infections). In addition, screening coverage is rarely 100% in 
clinical settings. Consequently, positivity in clinical settings may not reliably estimate 
population prevalence because women seeking care who are screened for chlamydia may 
differ from women seeking care who are not screened and women not seeking care. 
Therefore, population-based surveys with chlamydia prevalence estimates are more useful to 
inform national screening recommendations for the general population.
The objective of our study was to determine factors associated with prevalent chlamydial 
infection in a nationally representative sample of women aged 26 to 39 years participating in 
the National Health and Nutrition Examination Survey (NHANES).
The National Health and Nutrition Examination Survey is a series of cross-sectional, 
household surveys. Using a complex, multistage, probability sampling frame, NHANES is 
designed to be representative of the US civilian, noninstitutionalized population.9 After 
providing written informed consent, women participating in NHANES were interviewed and 
examined. Urine specimens collected from women aged 14 to 39 years were tested for 
Chlamydia trachomatis by nucleic acid amplification tests (NAATs), according to the 
manufacturers’ instructions.10 From 1999 to 2002, a ligase chain reaction assay (LCx; 
Abbott Laboratories, Abbott Park, IL) was used, and for the remaining cycles, the Becton 
Dickinson Probe Tec (Becton Dickinson, Franklin Lakes, NJ) was used. The study protocol 
was reviewed and approved by an institutional review board at the CDC.
For our analyses, data from women aged 26 to 39 years that were collected during six 2-year 
NHANES cycles (1999–2010) were aggregated and analyzed. We report prevalence of 
chlamydial infection by self-reported demographics and sexual behaviors. Estimates were 
weighted to be nationally representative and to account for oversampling and nonresponse.11 
We did not conduct statistical tests of significance but, instead, provide 95% confidence 
intervals (CIs) as measures of precision of estimates.12 Prevalence estimates with relative 
standard errors (RSEs) greater than 30%, but less than 40% are noted and are considered 
unstable and should be interpreted with caution.13 Exploratory analyses conducted with 
other variables collected in NHANES that had RSEs greater than 40% are not reported. 
Analyses were conducted in SAS v9.13 (SAS Institute Inc, Cary, NC) accounting for the 
complex survey design.
From 1999 to 2010, 3875 women aged 26 to 39 years participated in NHANES and were 
interviewed, examined, and tested for chlamydia. Overall chlamydia prevalence was 1.2% 
(95% CI, 0.8%–1.7%) (Table 1). Prevalence varied by race/ethnicity, with highest prevalence 
among black, non-Hispanic women (2.5%; 95% CI, 1.7%–3.6%), and by marital status, with 
highest prevalence among women who reported being widowed, divorced, or separated 
(2.7%; 95% CI, 1.4%–5.4%). Women who reported having less than a high school education 
or general education development (GED) had a higher prevalence than did women with 
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more education. Prevalence among women with health insurance was 1.0% (95% CI, 0.7%–
1.6%) and was 1.8% (95% CI, 0.9%–3.6%) among women without health insurance. 
Prevalence was highest among women who reported 2 or more sex partners in the last 12 
months (2.9%; 95% CI, 1.4%–5.7%) and among women who never used oral contraceptives 
or Depo-provera/injectables (3.4%; 95% CI, 2.0%–6.0%).
This is the first report to identify predictors of chlamydial infection in older women in a 
nationally representative sample using prevalence estimates from urine-based chlamydia 
screening. We document a low overall prevalence of chlamydial infection in this age group, 
as well as differences in prevalence by sociodemographics including race/ethnicity and 
educational attainment and self-reported sexual behaviors. These findings do not suffer from 
the limitations of studies identifying predictors of chlamydial infection diagnosed in clinical 
settings because the study population was nationally representative and not limited to a 
health care seeking population.
Lower educational attainment is a marker of current socioeconomic status.14 Our finding of 
a higher chlamydia prevalence in women with less than a high school education supports the 
notion that socioeconomic status may be an indirect determinant of sexually transmitted 
diseases.15 The racial/ethnic disparities in the NHANES prevalence estimates are less 
pronounced than those in chlamydia case-report data.16 This finding is not surprising 
because case-report data are likely influenced by differential screening17 and reporting 
practices, as well as missing race/ethnicity data, which may magnify disparities.16 Still, the 
racial/ethnic disparities in the NHANES data are noteworthy. It is likely that race/ethnicity 
and socioeconomic status are markers of other predictors of chlamydial infection, such as 
decreased access to routine health care and involvement in sexual networks with higher 
prevalence of disease.11 Access to routine health care is also likely influenced by health 
insurance coverage. Observed differences in prevalence by current insurance coverage are 
similar to findings from another nationally representative survey of young adults, which 
found that chlamydia prevalence was higher in men and women without continuous health 
insurance coverage.18
Differences in prevalence by self-reported sexual behaviors suggest that sexual history may 
be useful in identifying older women at higher-risk for chlamydial infection. Having 
multiple sexual partners in the last 12 months increases a woman’s opportunity for exposure 
to chlamydia. A clinic-based study in California also found sexual risk factors to be 
predictive of chlamydial infection in older women.19 In addition to new and multiple sex 
partners, the California study identified “possible concurrency” (measured by the question 
“At any time within the past 12 months, did any of your male partners have sex (of any type) 
with someone else while they were still in a sexual relationship with you?”) as a predictor of 
chlamydial infection in older women. Previous research has suggested that hormonal 
contraceptives may increase chlamydia risk20 perhaps through physiological mechanisms 
(e.g., increased susceptibility) and behavior change (e.g., decreased condom use). In our 
data, we found a higher prevalence among women reporting that they have never used oral 
contraceptives or longer-acting birth control methods such as Depo-provera/injectables. It is 
possible that women using hormonal contraceptives may have increased risk of infection but 
were less likely to have a prevalent infection because they have access to or use routine 
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reproductive health care, increasing their opportunities for routine sexually transmitted 
disease testing and treatment.
Although population-based survey data are better than clinic-based data for identifying 
predictors of chlamydial infection in the general population, our analysis has several 
limitations. Even after aggregating multiple survey cycles, small sample sizes limited our 
ability to examine prevalence by all possible relevant characteristics measured in NHANES 
(e.g., prior chlamydial infection and type of health insurance) and to cross-stratify variables 
to identify independent predictors or to develop weighted risk scores. We were limited to 
data collected consistently in all 6 survey cycles, and some important predictors of 
chlamydial infection in older women may not be included (e.g., concurrency and condom 
use). Chlamydia diagnosis was made using urine-based NAATs, which, at the time of the 
surveys, were the preferred specimen for chlamydia screening in women not undergoing a 
pelvic examination.21 Studies suggest that NAATs based on vaginal specimens may have 
higher sensitivity than urine specimens, which could lead to misclassification bias in our 
study.22 Finally, to increase the stability of our estimates, we combined all survey cycles and 
did not account for any changes in prevalence over time.
These findings support the current CDC recommendation that women older than 25 years 
should not be routinely screened for chlamydia, given the low prevalence of disease in this 
population. Although we identified predictors of chlamydial infection in older women, most 
subgroups had a prevalence of less than 3%, a cut-point often used in determining cost-
effectiveness of routine screening.1 Although some studies have shown that chlamydia 
screening in women can be cost-effective from a societal perspective at lower prevalence, 
few have evaluated screening in prevalence below 2%.23,24 Thus, these data did not identify 
national criteria for screening women older than 25 years. The National Health and Nutrition 
Examination Survey is currently the only nationally representative survey that includes C. 
trachomatis testing of older women, so it is unlikely that any other surveys will provide 
national, population-based prevalence estimates of women older than 25 years in the near 
future. However, it is likely that there are subpopulations of older women in which routine 
screening is indicated, particularly among women seeking clinical care in high-prevalence 
settings. Guided by the existing national screening recommendations, STD programs should 
consider conducting targeted prevalence studies (e.g., for a defined period, screen all women 
accessing care in a clinical setting and identify predictors of infection in asymptomatic 
women) to determine appropriate screening criteria for women older than 25 years accessing 
clinical care. However, criteria to identify and screen high-risk populations of older women 
should not take away from resources needed to provide screening coverage in younger 
women, the population at highest risk.
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TABLE 1.
Estimated Chlamydia Prevalence Among Women Aged 26 to 39 Years, NHANES, 1999 to 2010
n/N Weighted Percent 95% CI, %
Overall 51/3875 1.2 0.8–1.7
Demographics
 Age, y
  26–30 21/1459 1.4 0.8–2.5
  31–39 30/2416 1.1 0.7–1.8
 Race/Ethnicity
  Black, non-Hispanic 19/767 2.5 1.7–3.6
  Mexican American 13/869 1.5 0.9–2.5
  White, non-Hispanic 12/1741 0.7 0.4–1.5*
 Marital status
  Married/Living with partner 23/2617 0.8 0.4–1.3
  Widowed/Divorced/Separated 12/462 2.7 1.4–5.4*
  Never married 16/722 1.9 1.1–3.3
 Education
  HS/GED or less 32/1711 2.0 1.2–3.2
  >HS/GED 19/2163 0.7 0.4–1.2
 Currently has health insurance
  Yes 34/2913 1.0 0.7–1.6
  No 17/944 1.8 0.9–3.6*
Sexual behaviors
 Age at first sex, y
  <16 13/915 1.1 0.6–2.1*
  ≥16 years† 29/2354 1.2 0.7–1.9
 No. sex partners in the last 12 mo
  0–1 27/2893 0.8 0.5–1.3
  2+ 15/464 2.9 1.4–5.7
 Ever used oral contraceptives or Depo-provera/injectables
  Yes 25/2851 0.7 0.4–1.2
  No 18/566 3.4 2.0–6.0
*
Estimate has an RSE greater than 30% but less than 40% and should be interpreted with caution.
†
Includes women who reported never having sex.
HS indicates high school.
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